Doripenem
Doripenem is a pharmaceutical drug with 23 clinical trials. Historical success rate of 78.3%.
Success Metrics
Based on 18 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
78.3%
18 of 23 finished
21.7%
5 ended early
0
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Clinical Trials (23)
PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections
Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients
A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects
A Study of Doripenem in Infants Less Than 12 Weeks of Age
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
Doripenem in the Treatment of Hospital-Acquired Pneumonia
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 23